TAL1 and acute lymphoblastic leukemia: Interestingly, nearly 30% of pediatric TAL1+ T-ALL patients have heterozygous loss-of-function mutations in USP7, a deubiquitinating enzyme that interacts with E proteins, and other leukemia-associated proteins, and is associated with decreased E protein target gene expression and increased cell growth (73).